ESC 365 - Using empagliflozin for HFpEF treatment - what does this look like in practice?

Back

Open Access

Using empagliflozin for HFpEF treatment - what does this look like in practice?

Session: A new era for HFpEF – Exploring the role of empagliflozin in practice

Topic: Chronic Heart Failure

Speaker: Doctor S. Zieroth (Winnipeg, CA)

Sponsored by Boehringer Ingelheim and Eli Lilly and Company

Event: Heart Failure 2022

Congress Presentation

About the speaker

Doctor Shelley Zieroth

University of Manitoba, Winnipeg (Canada)

47 presentations

3 followers

3 more presentations in this session

Welcome and introduction.

Speaker: Professor A. Stewart Coats (Sydney, AU)

Access

Slides

Video

What is the evidence for empagliflozin in HF?

Speaker: Professor J. Butler (Dallas, US)

Access

Slides

Video

Panel discussion and close.

Speaker: Professor A. Stewart Coats (Sydney, AU)

Access

Slides

Video

Access the full session

A new era for HFpEF – Exploring the role of empagliflozin in practice

Speakers: Doctor S. Zieroth, Professor A. Stewart Coats, Professor J. Butler, Professor A. Stewart Coats

Access

Video

About the event

Heart Failure 2022

21 May - 24 May 2022

Sessions Presentations

Congress

Using empagliflozin for HFpEF treatment - what does this look like in practice?

About the speaker

Doctor Shelley Zieroth

3 more presentations in this session

Welcome and introduction.

What is the evidence for empagliflozin in HF?

Panel discussion and close.

Access the full session

A new era for HFpEF – Exploring the role of empagliflozin in practice

About the event

Heart Failure 2022

ESC 365 is supported by